Page 178 - ACCCN's Critical Care Nursing
P. 178

Psychological Care 155

             151.  Perras B, Meier M, Dodt C. Light and darkness fail to regulate melatonin   157.  Ibrahim MG, Bellomo R, Hart GK, Norman TR, Goldsmith D et al. A double-
                release  in  critically  ill  humans.  Intensive  Care  Med  2007;  33(11):   blind placebo-controlled randomised pilot study of nocturnal melatonin in
                1954–8.                                              tracheostomised patients. Crit Care Resusc 2006; 8(3): 187–91.
             152.  Cabello B, Thille AW, Drouot X, Galia F, Mancebo J et al. Sleep quality in   158.  Bourne RS, Mills GH, Minelli C. Melatonin therapy to improve nocturnal
                mechanically  ventilated  patients:  comparison  of  three  ventilatory  modes.   sleep in critically ill patients: encouraging results from a small randomised
                Crit Care Med 2008; 36(6): 1749–55.                  controlled trial. Crit Care 2008; 12(2): R52.
             153.  Bourne RS, Mills GH. Sleep disruption in critically ill patients – pharmaco-  159.  Shilo L, Dagan Y, Smorjik Y, Weinberg U, Dolev S et al. Effect of melatonin
                logical considerations. Anaesthesia 2004; 59(4): 374–84.  on sleep quality of COPD intensive care patients: a pilot study. Chronobiol
             154.  Hardin KA. Sleep in the ICU: potential mechanisms and clinical implica-  Int 2000; 17(1): 71–6.
                tions. Crit Care Med 2009; 136(1): 284–94.        160.  Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of
             155.  Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L et al. Efficacy   melatonin. Sleep Med Rev 2005; 9(1): 11–24.
                and  safety  of  exogenous  melatonin  for  secondary  sleep  disorders  and     161.  Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I et al. Effects of
                sleep  disorders  accompanying  sleep  restriction:  meta-analysis.  BMJ  2007;   exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 2005; 9(1):
                332(7538): 385–93.                                   41–50.
             156.  Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L et al. The efficacy   162.  Iber C, Ancoli-Israel S, Chesson A, Quan SF. AASM manual for the scoring of
                and  safety  of  exogenous  melatonin  for  primary  sleep  disorders:  a  meta   sleep and associated events: rules, terminology and technical specification. West-
                analysis. J Gen Intern Med 2005; 20(12): 1151–8.     chester, IL: American Academy of Sleep Medicine; 2007.
   173   174   175   176   177   178   179   180   181   182   183